Provides identification of potential patient safety issues and
actionable insight into clinical trial site performance
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--
Quintiles, the world’s largest biopharmaceutical services company, today
announced the addition of advanced statistical monitoring and predictive
analytics capabilities to its risk-based monitoring (RBM) solution.
Predictive and Advanced Analytics combine Quintiles’ experience as the
RBM leader with its deep therapeutic and strong statistical sciences
heritage to enable study teams to identify the right signals and predict
clinical trial site performance and potential patient safety issues.
This Smart News Release features multimedia. View the full release here:
http://www.businesswire.com/news/home/20150615005387/en/
Predictive and Advanced Analytics are the first such model-based
capabilities fully integrated into an RBM solution on the market today.
Underpinned by the award-winning Quintiles Infosario®
technology platform and Quintiles’ deep data resources, these new
capabilities improve precision in risk identification by better
understanding underlying “white noise” from safety trigger processes.
“The ultimate goal of risk-based monitoring is to increase the
efficiency of drug development while improving quality and patient
safety,” said Margaret Keegan, senior vice president, Data Sciences &
Strategy at Quintiles. “The ability to cut through all the noise and
predict potential risks before they occur means we can target the right
action at the right place at the right time. It is a major step forward
in improving quality and productivity in the next generation of RBM
execution.”
Quintiles is the RBM market leader currently engaged in more than 130
studies using RBM processes and policies, across more than 26,000 sites
and 260,000 patients. Compliant with U.S. Food and Drug Association,
European Medicines Agency and TransCelerate
guidance, Predictive and Advanced Analytics use unique statistical
algorithms specifically designed for optimal RBM execution. The
capabilities combine inputs across multiple variables including
operational performance and study data to provide unprecedented insights
into potential study risks.
“Being able to target patients and sites with this level of accuracy
takes RBM to a new level in terms of both speed and quality,” said
Teresa Lamantia, senior vice president, Knowledge Management at
Quintiles. “The ability to focus resources where they’re needed to
protect patient safety and the integrity of the trial is a welcome
advance for all of us working to transform clinical development.”
Quintiles’ experts will be available to discuss RBM and the new
Predictive and Advanced Analytics functionality at its booth at the
upcoming Drug Information Association (DIA) conference June 14-18, 2015,
in Washington, D.C. In addition, a discussion of Predictive and Advanced
Analytics will be included in a Quintiles presentation at 12 p.m. EDT,
June 16 at DIA’s Innovation Theater. For more information about
Quintiles’ Predictive and Advanced Analytics capabilities, visit the
Quintiles booth at DIA (#601) or watch this video: www.quintiles.com/library/videos/predictive-and-advanced-analytics.
About Quintiles
Quintiles (NYSE:Q) helps biopharma and other healthcare companies
improve their probability of success by connecting insights from our
deep scientific, therapeutic and analytics expertise with superior
delivery for better outcomes. From advisory through operations,
Quintiles is the world’s largest provider of product development and
integrated healthcare services, including commercial and observational
solutions. Conducting operations in approximately 100 countries,
Quintiles is a member of the FORTUNE 500 and has been named to FORTUNE’s
list of the “World’s Most Admired Companies.” To learn more, visit www.quintiles.com.
Click here
to subscribe to Mobile Alerts for Quintiles.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150615005387/en/
Source: Quintiles